-
NIDA HIV Seminar Series: Let’s talk PrEP! Oct. 23, 1pm ET (virtual)
Questions about HIV PrEP and how it relates to people with substance use disorders? The NIDA HIV Research Program has invited some HIV clinical research experts and people living with HIV and substance use disorders to join us in our next virtual Seminar, “Let’s Talk PrEP”, October 23rd, 1-2:30 pm. The seminar includes Drs. Rupa Patel from Whitman-Walker Health and the CDC; Dr. Jaimie Meyer from Yale, and Dr. Hansel Tookes from the University of Miami. Register for the webinar here!
-
Recommended Resource: Facts About Fentanyl (Addiction Policy Forum)
As fentanyl continues to impact communities at an unprecedented rate, understanding its potency and dangers is critical to reducing harm. By raising awareness and promoting life-saving measures like naloxone, we can work toward preventing overdoses and saving lives. This new video explainer from the Addiction Policy Forum highlights the increase of synthetic opioids like fentanyl, overdose risks, the increase in counterfeit pills containing fentanyl nationwide, and the importance of naloxone access and overdose prevention education. The video is available in English as well as in multiple additional languages.
-
News: U.S. Overdose Deaths Plummet, Saving Thousands of Lives (NPR)
NPR Exclusive: U.S. Overdose Deaths Plummet, Saving Thousands Of Lives. According to NPR (9/18, Mann, 3.69M), state level public health data, “for the first time in decades,” may point to “a sudden and hopeful drop in drug overdose deaths across the US.” University of North Carolina researcher Dr. Nabarun Dasgupta posted data he said show that “in the states that have the most rapid data collection systems, we’re seeing declines of twenty percent, thirty percent.” NIDA Director Dr. Nora Volkow called the decline “exciting,” adding, “This looks real. This looks very, very real.” Volkow said, “Expansion of naloxone and medications for opioid use disorder – these strategies worked.” NPR adds that CDC…
-
Recording available! CTN TH&TM SIG: California Contingency Management Project
Did you miss September’s Telehealth & Telemedicine SIG meeting? No worries, the recording from this presentation is now available in the CTN Dissemination Library! Lessons Learned from Implementation of the California Contingency Management Pilot Presenters: Thomas E. Freese, PhD, and Darren Urada, PhD More than half of individuals admitted for specialty substance use disorder treatment in California identify stimulants as their primary or secondary drug, yet many people who use stimulants do not seek treatment. Numerous studies have shown that contingency management (CM) is the most effective treatment for stimulant use disorder. California’s innovative Recovery Incentives Program is a groundbreaking initiative that benefits California and serves as a potential blueprint…
-
CTN Primary Care SIG Meeting: OUD Treatment in Primary Care (Sept. 23, 12pm ET)
Join the CTN Primary Care SIG for their next meeting, featuring Linda Zittleman, MSPH, and Don Nease, Jr., MD (both of University of Colorado Anschutz Medical Campus Department of Family Medicine), talking about: The Odyssey of HOMER: lessons from a pragmatic trial on opioid use disorder treatment in primary care.” September 23, 202412-1pm EST Linda Zittleman, MSPHSenior InstructorHigh Plains Research Network DirectorUniversity of Colorado Anschutz Medical Campus Department of Family Medicine Don Nease, Jr. MDDirector of Community Engagement & Health EquityColorado Clinical & Translational Sciences InstituteProfessor and Green-Edelman Chair for Practice-Based ResearchUniversity of Colorado Anschutz Medical Campus Department of Family Medicine Join the webinar here (no registration required; passcode 291918) Interested in presenting at a…
-
New from CTN-0080: PATHS Toolkit about OUD and Pregnancy Now Available!
The CTN-0080 (MOMs) team has developed a set of dissemination materials around messaging for medications for opioid use disorder (MOUD) in pregnant and postpartum individual, now available on the CTN Dissemination Library website! The Prenatal Action for Taking Health Steps (PATHS) Toolkit includes flyers, info sheets, posters, an education video, and social media images and short videos (“Reels”), all available for download and sharing. There’s also a discussion guide that can be used to direct conversations about MOUD in pregnant/postpartum people either in a group or individual settings, as well as a set of external links and resources that can be helpful to the public. The materials are available in…
-
Protocol Update: CTN-0100 (RDD)
On August 30, 2024, the CTN-0100 study reached our goal of 950 BUP randomizations in the Retention Phase of the study! This momentous milestone marked the end of recruitment for this phase. The first randomization occurred on June 10, 2021, and as of September 16, 2024 there have 1,139 randomizations overall (951 BUP, 188 Vivitrol). Additionally, five sites achieved their original recruitment goal and three sites reached or surpassed 100 overall randomizations. The Lead Investigators and Project Team express sincere appreciation to the 18 study sites for their unwavering dedication and commitment to this endeavor over the past several years. As we continue to focus on the Discontinuation Phase of…
-
News from the Appalachian Node
Laura Lander, MSW, AADC, co-PI of the CTN Appalachian Node and an associate professor in the West Virginia University School of Medicine’s Department of Behavioral Medicine and Psychiatry and Department of Neuroscience, was recently appointed to the statewide expert panel of the West Virginia First Foundation. In the appointment, Lander will be part of a comprehensive group of six experts that assist the Foundation’s board in making financial decisions regarding strategies for abating the opioid epidemic in local communities around the state. “I am honored to have been chosen for the expert panel and entrusted with making decisions on how best to help the people of West Virginia most impacted by…
-
New in the Library (August-September 2024)
Here are the latest items added to the CTN Dissemination Library for August – September 2024 (this post will be updated as new items come in): Barriers and Facilitators to Implementing Treatment for Opioid Use Disorder in Community Hospitals. Shearer R, et al. Journal of Substance Use and Addiction Treatment 2024 (in press). (CTN-0098) A Scoping Review of Social Determinants of Health’s Impact on Substance Use Disorders Over the Life Course. Lin C, et al. Journal of Substance Use & Addiction Treatment 2024 (in press). Impact of COVID-19 on MOUD Retention in a Sample of Rural Primary Care Patients: A Secondary Analysis of Electronic Health Records. Calhoun S, et al.…
-
News from the PNW Node: Videos & Factsheets about XR-Injectable Buprenorphine
Buprenorphine is one of three medications (methadone and naltrexone being the other two) approved for use to treat opioid use disorder. It is available as a film or tablet, and more recently as two long-acting extended-release injectables. Sublocade™ was first to be approved by the FDA in November 2017. More recently, in May 2023, Brixadi™ received approval. In January 2024 it was added to the WA state Medicaid formulary. Fewer clinicians have experience using Brixadi™ than Sublocade™. The CTN Pacific Northwest Node has developed a set of videos and information sheets to help prescribers in their conversations with patients interested in these buprenorphine options. The videos (which are also available in an audio-only podcast format)…
